Wells Fargo analyst Derek Archila lowered the firm’s price target on Kezar Life Sciences (KZR) to $7 from $9 and keeps an Equal Weight rating on the shares. The firm thinks zetomipzomib demonstrated interesting signs of activity in autoimmune hepatitis, though some of the baseline imbalances worry Wells as well as the lack of a clear reg path for the indication as a whole. The firm remains on the sidelines.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZR: